EligibleTrials

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Recruiting · NCT06116526 · Interventional (participants receive a specific treatment) · Lead sponsor: Johns Hopkins University

View the official record on ClinicalTrials.gov →
Eczema

Interventions studied

Dupilumab - DiscontinuationDupilumab - Dose ReductionDupilumab - Standard Dose

What this trial is about

This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

Who can take part

Age range
1 Year to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.